In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyPresenters:Georgios Gakis, MD Professor of Urology, Staff UrologistUniversity Hospital of Würzburg Würzburg, GermanyMario Wolfgang Kramer, MD, PhD Consultant UrologistVice Director, UrologyUniversity Hospital Schlewig-Holstein Campus LübeckLübeck, GermanyContent based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand webcast:https://bit.ly/3kJC5SL

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related